Equity Overview
Price & Market Data
Price: $0.0₃3
Daily Change: $0.00 / 0.00%
Range: $0.0₃3 - $0.0₃3
Market Cap: $1,411
Volume: 28,106
Performance Metrics
1 Week: 100.0%
1 Month: %
3 Months: -66.67%
6 Months: %
1 Year: -99.99%
YTD: -66.67%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.